 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment |
| Bo Hyun Kim, Joong-Won Park |
|
J Liver Cancer. 2021;21(2):124-138. Published online September 30, 2021 DOI: https://doi.org/10.17998/jlc.2021.09.23 |
|
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment Journal of Liver Cancer. 2021;21(2):124-138  Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma Journal of Hepatocellular Carcinoma. 2016;Volume 3:31-36 Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma Liver Cancer. 2016;5(4):235-244 Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma Liver Cancer. 2018;7(4):305-311 PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib Annals of Oncology. 2019;30:iv105 Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction Journal of Hepatocellular Carcinoma. 2021;Volume 8:1147-1158 Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond Current Oncology. 2020;27(13):173-180 Comprehensive Consideration before the Decision-Making of the Systemic Treatment in Patients with Advanced Hepatocellular Carcinoma Liver Cancer. 2019;9(2):221-222 Hepatic reserve and the other conditions for regorafenib as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib in Japanese practical setting Annals of Oncology. 2017;28:x71 Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma OncoTargets and Therapy. 2014;1875 |
